When TIGIT inhibition was combined with anti-PD-1 inhibition in vitro, it was found to enhance tumor antigen specific CD8+ T cell expansion and activity, as compared with anti-PD-1 inhibition alone [64]. Here, CD8A is linked to neoplasm.